James C Geoghegan

List of Publications by Year
in descending order

19 papers	2,868 citations	430874 18 h-index	794594 19 g-index
19 all docs	19 docs citations	19 times ranked	4446 citing authors

#	Article	IF	Citations
1	Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal, 2003, 22, 6267-6276.	7.8	963
2	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	12.6	285
3	Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8546-8551.	7.1	211
4	Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone, 2004, 35, 828-835.	2.9	198
5	Protease-resistant Prion Protein Amplification Reconstituted with Partially Purified Substrates and Synthetic Polyanions. Journal of Biological Chemistry, 2005, 280, 26873-26879.	3.4	177
6	Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell Differentiation Is Indirect and Mediated by Bone Morphogenetic Proteins. Journal of Biological Chemistry, 2005, 280, 2498-2502.	3.4	160
7	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	11.9	153
8	Selective Incorporation of Polyanionic Molecules into Hamster Prions. Journal of Biological Chemistry, 2007, 282, 36341-36353.	3.4	100
9	Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs, 2016, 8, 454-467.	5.2	91
10	Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex. Journal of Biological Chemistry, 2004, 279, 36293-36298.	3.4	88
11	Species-Dependent Differences in Cofactor Utilization for Formation of the Protease-Resistant Prion Protein in Vitro. Biochemistry, 2010, 49, 3928-3934.	2.5	85
12	Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone, 2004, 35, 448-454.	2.9	78
13	Copper (II) ions potently inhibit purified PrPres amplification. Journal of Neurochemistry, 2006, 96, 1409-1415.	3.9	53
14	Trans-Dominant Inhibition of Prion Propagation In Vitro Is Not Mediated by an Accessory Cofactor. PLoS Pathogens, 2009, 5, e1000535.	4.7	52
15	Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. MAbs, 2016, 8, 941-950.	5.2	51
16	Dissociation of Infectivity from Seeding Ability in Prions with Alternate Docking Mechanism. PLoS Pathogens, 2011, 7, e1002128.	4.7	43
17	Sialic Acid Deposition Impairs the Utility of AAV9, but Not Peptide-modified AAVs for Brain Gene Therapy in a Mouse Model of Lysosomal Storage Disease. Molecular Therapy, 2012, 20, 1393-1399.	8.2	40
18	Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double-stranded RNA-binding Domain Structure. Molecular Therapy - Nucleic Acids, 2012, 1, e53.	5.1	28

#	Article	IF	Citations
19	Chondroitin Sulfate is the Primary Receptor for a Peptide-Modified AAV That Targets Brain Vascular Endothelium In Vivo. Molecular Therapy - Nucleic Acids, 2014, 3, e202.	5.1	12